Vaxcyte PCVX 深 沪
已收盘 08-21 16:00:00 美东时间
62.62
+1.280
+2.09%
华盛通- 最 高63.98
- 今 开61.60
- 成交量 114.15万股
- 最 低 61.60
- 昨 收 61.34
- 总市值 93.18亿
- 52周最高 65.00
- 市盈率 静 --
- 换手率 0.77%
- 52周最低 30.81
- 委 比 66.48%
- 总股本 1.49亿
- 历史最高 121.055
- 量 比 1.34
- 振 幅 3.88%
- 历史最低 15.51
- 每 手 1
- 风险率 8.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Seth Klarman's Baupost adds Pershing Square in Q2; boosts Amazon, Alphabet
Seth Klarman's Baupost initiated a new position in CME (CME) and Pershing Square (PS) during Q2, while exiting Willis Towers Watson (WTW). Baupost, one of the largest hedge funds in the world, disclos...
08-14 05:46
财报速睇 | Vaxcyte 2026财年Q2营收0.00亿美元，同比持平；归母净利润亏损2.84亿美元，同比亏损扩大70.7%
华盛资讯8月6日讯，Vaxcyte公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比持平，归母净利润亏损2.84亿美元，同比亏损扩大70.7%。
08-06 09:22
财报速睇 | Vaxcyte 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损2.84亿美元，同比亏损扩大70.1%
华盛资讯8月6日讯，Vaxcyte公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损2.84亿美元，同比亏损扩大70.1%。
08-06 08:32
Vaxcyte Q2 EPS $(1.97) Beats $(2.22) Estimate
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.97) per share which beat the analyst consensus estimate of $(2.22) by 11.26 percent. This is a 61.48 percent decrease over losses of $(1.22) per share from the same period last year.
08-06 06:33
Vaxcyte to Participate in Upcoming Investor Conferences
Vaxcyte, Inc. announced that its management will participate in one-on-one meetings at the Leerink Partners Therapeutics Forum on July 15, 2026, and the BTIG Virtual Biotechnology Conference on July 28, 2026. The company, focused on developing high-fidelity vaccines, is advancing several candidates, including VAX-31 and VAX-24 for pneumococcal disease prevention, VAX-A1 for Group A Strep, and VAX-GI for Shigella. Vaxcyte utilizes its XpressCF pla...
07-08 20:05
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away fro...
06-30 01:35
Mizuho Securities Sticks to Its Buy Rating for Vaxcyte (PCVX)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Vaxcyte on June...
06-21 16:17
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
Vaxcyte has initiated a Phase 1 trial for VAX-A1, a vaccine candidate targeting Group A Streptococcus (Group A Strep), a leading cause of bacterial infections globally with no approved vaccine. The study, conducted in 80 healthy adults, aims to evaluate safety, tolerability, and immune responses. Group A Strep causes approximately 800 million cases and over 600,000 deaths annually, highlighting the urgent need for a preventive solution. VAX-A1 is...
06-02 20:05
Vaxcyte shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Vaxcyte shares are trading lower after the company reported worse-than-expected...
05-08 03:05
